Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice

Lung Cancer

Volumn 65, Issue 3, 2009, Pages 284-289

  Kishino, Daizo ^a   Kiura, Katsuyuki ^a   Takigawa, Nagio ^a   Katayama, Hideki ^a   Kuyama, Shoichi ^a   Sato, Ken ^a   Okada, Toshiaki ^a   Ohashi, Kadoaki ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

A J mice; Carcinogenesis; Chemoprevention; EGFR; Gefitinib; Pulmonary toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; N NITROSAMINE 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; PYRIDINE DERIVATIVE; TOBACCO SMOKE; UNCLASSIFIED DRUG; WATER;

A J MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER PREVENTION; CELL TRANSFORMATION; DATA ANALYSIS; DRUG CARCINOGENICITY; DRUG MEGADOSE; DRUG TARGETING; FEEDING; FEMALE; LOW DRUG DOSE; LUNG CARCINOGENESIS; LUNG FIBROSIS; LUNG TOXICITY; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; STAINING; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS, ENVIRONMENTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; NITROSAMINES; PULMONARY FIBROSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TUMOR BURDEN;

EID: 67651252080     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.021     Document Type: Article

References (30)

1. Global cancer rates could increase by 50% to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/pr27/en/.
2. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., editors. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/. Center for Cancer Control and Information Services, National Cancer Center, Japan http://ganjoho.ncc.go.jp/professional/statistics/statistics.html).
3. Wang Z.Y., Hong J.Y., Huang M.T., Reuhl K.R., Conney A.H., and Yang C.S. Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res 52 (1992) 1943-1947
4. Mimoto J., Kiura K., Matsuo K., Yoshino T., Takata I., Ueoka H., et al. (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. Carcinogenesis 21 (2000) 915-919
5. Rioux N., and Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58 (1998) 5354-5360
6. Saffiotti U., Montesano R., Sellakumar A.R., and Borg S.A. Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20 (1967) 857-864
7. Willett W.C., Polk B.F., Underwood B.A., Stampfer M.J., Pressel S., Rosner B., et al. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med 310 (1984) 430-434
8. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
9. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 7 Suppl 4 (2002) 31
10. Dy G.K., and Adjei A.A. Novel targets for lung cancer therapy. Part I. J Clin Oncol 20 (2002) 2881-2894
11. Abell C.W., Falk H.L., Shimkin M.B., Weisburger E.K., Weisburger J.H., and Gubareff N. Uracil mustard: a potent inducer of lung tumors in mice. Science 147 (1965) 1443-1445
12. Hecht S.S., Isaacs S., and Trushin N. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis 15 (1994) 2721-2725
13. Langenfeld J., Lonardo F., Kiyokawa H., Passalaris T., Ahn M.J., Rusch V., et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 13 (1996) 1983-1990
14. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53 suppl. 10 (1993) 2379-2385
15. Lonardo F., Dragnev K.H., Freemantle S.J., Ma Y., Memoli N., Sekula D., et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8 (2002) 54-60
16. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110
17. Gefitinib Iressa 250 mg Tablet No. 28 New Drug Approval Package (NAP) Japan Pharmaceutical Education Center, Yakuji Nipposha, Tokyo, Japan; 2003.
18. Leopold W.R., Batzinger R.P., Miller E.C., Miller J.A., and Earhart R.H. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. Cancer Res 41 11 Pt 1 (1981) 4368-4377
19. Hisamoto A., Kondo E., Kiura K., Okada T., Hosokawa S., Mimoto J., et al. Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice. Lung Cancer 58 (2007) 15-20
20. Belinsky S.A., Devereux T.R., Maronpot R.R., Stoner G.D., and Anderson M.W. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res 49 (1989) 5305-5311
21. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
22. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
23. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
24. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
25. Kitahashi T., Takahashi M., Yamada Y., Oghiso Y., Yokohira M., Imaida K., et al. Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. Cancer Sci 99 (2008) 241-245
26. Uchida A., Hirano S., Kitao H., Ogino A., Rai K., Toyooka S., et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 98 (2007) 357-363
27. Yan Y., Lu Y., Wang M., Vikis H., Yao R., Wang Y., et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 4 (2006) 971-981
28. Suzuki H., Aoshiba K., Yokohori N., and Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63 (2003) 5054-5059
29. Ishii Y., Fujimoto S., and Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 174 (2006) 550-556
30. Igarashi M, Yoshida M, Watanabe M, Abe M, Sugano S, Nakae D. Lung carcinogenesis induced by NNK in Ogg1 knockout mice. Proceedings of the 66th Annual Meeting of the Japanese Cancer Association. 2007.